ALEC
USDAlector Inc. Common Stock
Reaalajas hind
Hinnagraafik
Põhinäitajad
Turunäitajad
Avatud
$1.400
Kõrge
$1.435
Madal
$1.290
Maht
1.77M
Ettevõtte fundamentaalnäitajad
Turukapitalisatsioon
133.6M
Tööstusharu
Biotehnoloogia
Riik
United States
Kauplemisstatistika
Keskmine maht
2.62M
Börs
NMS
Valuuta
USD
52 nädala vahemik
Seotud uudised
Clinical Failure Halts Alector's Dementia Program, Company Reduces Workforce
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued; Alector cuts 49% of staff.
TD Cowen Downgrades Alector to Hold
TD Cowen analyst Yaron Werber downgrades Alector from Buy to Hold.
Cantor Fitzgerald Downgrades Alector to Neutral
Cantor Fitzgerald analyst Pete Stavropoulos downgrades Alector from Overweight to Neutral.
HC Wainwright & Co. Maintains Buy on Alector, Lowers Price Target to $5
HC Wainwright & Co. analyst Andrew Fein maintains Alector with a Buy and lowers the price target from $10 to $5.
William Blair Downgrades Alector to Market Perform
William Blair analyst Myles Minter downgrades Alector from Outperform to Market Perform.
BTIG Downgrades Alector to Neutral
BTIG analyst Thomas Shrader downgrades Alector from Buy to Neutral.
Alector Announces Topline Results from Latozinemab Phase 3 Trial in Individuals with Frontotemporal Dementia Due to a GRN Mutation and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (NASDAQ:ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of
Seotud aktsiad
Püsi kursis
Määrake hinnateavitused, hankige tehisintellekti analüüsi uuendusi ja reaalajas turuuudiseid.